Promising Interim Data in Phase 1/2 Hunter Syndrome Trial
source: shutterstock.com

Promising Interim Data in Phase 1/2 Hunter Syndrome Trial

Professionals from all corners of the world convene at SSIEM each year to discuss the latest groundbreaking discoveries. According to a report in BioSpace, one such breakthrough was presented by…

Continue Reading Promising Interim Data in Phase 1/2 Hunter Syndrome Trial
RDLA Webinar: Updates on the VALID Act, RUSP Alignment, Newborn Screening, and Precision Medicine for Kids
source: shutterstock.com

RDLA Webinar: Updates on the VALID Act, RUSP Alignment, Newborn Screening, and Precision Medicine for Kids

On September 28, 2022, the Rare Disease Legislative Advocates (RDLA) hosted their monthly webinar. These webinar help provide updates to the rare disease community on legislation and other policy initiatives…

Continue Reading RDLA Webinar: Updates on the VALID Act, RUSP Alignment, Newborn Screening, and Precision Medicine for Kids
FDA Grants Rare Pediatric Disease Designation to AVR-RD-05 for Hunter Syndrome
source: pixabay.com

FDA Grants Rare Pediatric Disease Designation to AVR-RD-05 for Hunter Syndrome

According to an article published in Yahoo, the FDA has recently granted the Rare Pediatric Disease designation to AVR-RD-05, a gene therapy for Hunter syndrome. This designation is reserved for…

Continue Reading FDA Grants Rare Pediatric Disease Designation to AVR-RD-05 for Hunter Syndrome
Natural Language Processing is Changing How We Research Rare Diseases
https://pixabay.com/en/africa-zebra-black-and-white-safari-1203936/

Natural Language Processing is Changing How We Research Rare Diseases

Diagnosing Rare Diseases Diagnosing rare diseases is historically difficult. Physicians are taught to think about horses instead of zebras because horses are abundantly more common. For instance, if you're tired…

Continue Reading Natural Language Processing is Changing How We Research Rare Diseases
Experimental Gene Therapy Program for Hunter Syndrome (MPS II) Begins Expanding
source: pixabay.com

Experimental Gene Therapy Program for Hunter Syndrome (MPS II) Begins Expanding

According to a story from PR Newswire, the biotechnology company REGENXBIO Inc. has recently announced plans to expand its RGX-121 developmental program. RGX-121 is being developed as a potential one-time…

Continue Reading Experimental Gene Therapy Program for Hunter Syndrome (MPS II) Begins Expanding
Kate Middleton Visits Boys with Hunter Syndrome and Dystonic Cerebral Palsy
source: pixabay.com

Kate Middleton Visits Boys with Hunter Syndrome and Dystonic Cerebral Palsy

  East Anglia's Children's Hospices in Norfolk, U.K., has recently opened up its new facilities after renovations. To celebrate this opening, Kate Middleton, the Duchess of Cambridge, visited and spoke…

Continue Reading Kate Middleton Visits Boys with Hunter Syndrome and Dystonic Cerebral Palsy
Company Seeks to Treat Hunter Syndrome (MPS II) in China With New Drug Application
liaoyiye / Pixabay

Company Seeks to Treat Hunter Syndrome (MPS II) in China With New Drug Application

According to a story from BioSpace, the biopharmaceutical company CANBridge Pharmaceuticals announced that it has recently submitted a New Drug Application with China's National Medicinal Products Administration (NMPA) for its…

Continue Reading Company Seeks to Treat Hunter Syndrome (MPS II) in China With New Drug Application
India Turns to Enzyme Replacement Therapy as it Seeks to Address Rare Diseases
klbz / Pixabay

India Turns to Enzyme Replacement Therapy as it Seeks to Address Rare Diseases

According to a story from health.economictimes.indiatimes.com, the country of India is currently beginning to take more steps in order to address the dire unmet medical need of its rare disease…

Continue Reading India Turns to Enzyme Replacement Therapy as it Seeks to Address Rare Diseases
Takeda Pharmaceutical Launches Trio of Enzyme Replacement Therapies in India to Treat Lysosomal Storage Disorders
source: pixabay.com

Takeda Pharmaceutical Launches Trio of Enzyme Replacement Therapies in India to Treat Lysosomal Storage Disorders

According to a press release from Takeda Pharmaceutical Company published by For Press Release, the Company has launched a collection of enzyme replacement therapies for use in the treatment of…

Continue Reading Takeda Pharmaceutical Launches Trio of Enzyme Replacement Therapies in India to Treat Lysosomal Storage Disorders
Experimental Treatment for Hunter Syndrome Earns Rare Pediatric Disease Designation and Orphan Drug Designation
DarkoStojanovic / Pixabay

Experimental Treatment for Hunter Syndrome Earns Rare Pediatric Disease Designation and Orphan Drug Designation

According to a story from globenewswire.com, the biopharmaceutical company Denali Therapeutics, Inc. has recently announced that its experimental product candidate DNL310, which is currently being developed as a treatment for…

Continue Reading Experimental Treatment for Hunter Syndrome Earns Rare Pediatric Disease Designation and Orphan Drug Designation

The Argument for Mandatory Newborn Screening and Government Subsidies for Rare Diseases in India

The State of Rare Disease in India There are 7,000 known rare diseases worldwide. The Organization for Rare Diseases India (ORDI) estimates 70 million people are affected by a rare diagnosis…

Continue Reading The Argument for Mandatory Newborn Screening and Government Subsidies for Rare Diseases in India

Researchers Fail to Find a Cure for MPS Through Genome Editing

The Daily News recently published an announcement by researchers at Sangamo Therapeutics showing the results of its first human trial to treat two rare genetic disorders through gene-editing technology. Gene-editing (or…

Continue Reading Researchers Fail to Find a Cure for MPS Through Genome Editing